The Peptune Brief
Every issue, in one place
The honest weekly read on peptides, hormones, and midlife. No hype, no fear-mongering — just what the evidence actually supports.
Issue 003
The FDA's own scientists just flagged the peptides it's about to review
Agency reviewers and agency leadership point in opposite directions, the GLP-1 muscle question, and the HRT timing myth that refuses to die.
Issue 002
The FDA vote is three weeks out — and the room has quietly changed
The committee that rejected every peptide in 2024 has quietly shrunk, the HRT pendulum swings back, and what "timing" really means (hint: it's never too late).
Issue 001
What the FDA decides this month, and the GLP-1 bone-loss story everyone's about to misread
The July hearing that's being oversold, a second review that's relevant to midlife skin, and why the order matters more than the molecule.
peptune.
Never miss an issue — get the Brief free in your inbox each week.
Subscribe to The Peptune Brief